Regeneron Pharmaceuticals signs 116,200 s/f expansion with BioMed Realty
Tarrytown, NY Regeneron Pharmaceuticals Inc. has signed a nine-year lease expansion with BioMed Realty Trust Inc. for 116,200 s/f at the Landmark at Eastview, bringing the campus to 99% leased. The life sciences company now leases 1.1 million s/f at The Landmark at Eastview campus. BioMed Realty was represented by Transwestern partner Matthew McDevitt in the transaction.
“We are proud to extend our valued relationship with Regeneron Pharmaceuticals,” said BioMed’s Alan Gold, chairman and chief executive officer. “Transwestern is a highly regarded firm that we’ve had the pleasure of working with on a number of significant biotech transactions along the East Coast, and we are excited to continue working with them to build leasing momentum at The Landmark.”
Owned and managed by BioMed Realty, The Landmark at Eastview is one of the largest multi-tenant science parks in the state.
Peter Capuciati and Alex Blue of Savills Studley represented Regeneron Pharmaceuticals in the transaction.
Manhattan, NY GFP Real Estate closed three office leasing transactions totaling 9,952 s/f at 322 Eighth Ave. in Chelsea, highlighting continued leasing momentum at the recently repositioned office
Walk down any New York block this year and you can feel it. The sidewalks are crowded, the storefronts are lit, and the energy that defines this city is back at full volume.
There was a time when an offering memorandum (OM) was pretty bare bones, some photos, a few bullet points on income, and a rent roll thrown in at the back. That used to get the job done. Not anymore. In 2025, buyers are sharper, faster, and more selective. They’re looking
Artificial intelligence (AI) is beginning to help transform lending by enhancing decision-making, improving risk management and streamlining operations. With AI-powered tools that analyze vast amounts of data, lenders are able to assess borrower creditworthiness more accurately and efficiently. AI can evaluate a wide range of factors,
You have a right to be concerned. I am always surprised at the companies that will negotiate the price of their new facility down to the last dollar, without thoroughly analyzing their